VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin
Phase 2
Small molecule
S
Sichuan Cancer Hospital and Research Institute
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
PD-L1 Negative
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
PD-L1 Negative
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
PD-L1 Negative
1 trial
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Recruiting
·
S
Sichuan Cancer Hospital and Research Institute
·
Phase 2
·
NCT06532591
·
20 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Sichuan Cancer Hospital and Research Institute company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
S
Sichuan Cancer Hospital and Research Institute
Related News